SI-BONE reports Q3 2023 record revenue of $34.0M (+29% YoY); raises FY23 guidance to $136-137M

SI-BONE, Inc.

2023-Q3 EPS reported -$0.86 revenue$100,027,000

Q3 revenue $34.0M (+29% YoY); US revenue $32.3M (+31% YoY).
Net loss improved to $10.0M ($0.25/sh) from $14.2M ($0.41/sh) YoY.
Adjusted EBITDA loss improved 44% to -$3.9M.
Raised fiscal 2023 revenue guidance to $136M-$137M from $132M-$134M.
Over 1,040 US active surgeons (+30% YoY); 90,000 procedures worldwide.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SI-BONE, Inc. reported the quarter ended September 30, 2023 results: revenue $34.0 million, net income $10.0 million, or $0.25 per diluted share, EPS $0.25 per diluted share. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $34.0 million
Net income: $10.0 million, or $0.25 per diluted share
EPS: $0.25 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2023. Recent Financial Highlights • Record worldwide revenue of $34.0 million for the third quarter 2023, representing approximately 29% growth over the corresponding period in 2022 • Record U.S. revenue of $32.3 million for the third quarter 2023,

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-23-000102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.